双表达或三表达淋巴瘤：免疫组化对弥漫性大B细胞淋巴瘤患者的预后影响 - Suppr

Suppr

超能文献

Double or triple-expressor lymphomas: prognostic impact of immunohistochemistry in patients with diffuse large B-cell lymphoma.

作者信息

Peña Camila, Villegas Pablo, Cabrera María Elena

机构信息

Hospital del Salvador, Santiago, Chile.

出版信息

Hematol Transfus Cell Ther. 2020 Apr-Jun;42(2):192-193. doi: 10.1016/j.htct.2019.04.002. Epub 2019 Jun 29.

DOI:10.1016/j.htct.2019.04.002

PMID:31395458

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7248506/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c76e/7248506/16464f6b7332/gr1.jpg

相似文献

Double or triple-expressor lymphomas: prognostic impact of immunohistochemistry in patients with diffuse large B-cell lymphoma.双表达或三表达淋巴瘤：免疫组化对弥漫性大B细胞淋巴瘤患者的预后影响

Hematol Transfus Cell Ther. 2020 Apr-Jun;42(2):192-193. doi: 10.1016/j.htct.2019.04.002. Epub 2019 Jun 29.

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.弥漫性大 B 细胞淋巴瘤中 MYC、BCL2 和/或 BCL6 额外拷贝的预后影响：与双/三打击淋巴瘤和双表达淋巴瘤的比较。

Diagn Pathol. 2019 Jul 17;14(1):81. doi: 10.1186/s13000-019-0856-7.

Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.“双打击”弥漫性大B细胞淋巴瘤及具有弥漫性大B细胞淋巴瘤和伯基特淋巴瘤之间特征的不可分类B细胞淋巴瘤的诊断：时机与方法，荧光原位杂交（FISH）与免疫组化（IHC）对比

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):90-9. doi: 10.1182/asheducation-2014.1.90. Epub 2014 Nov 18.

Primary, non-germinal center, double-expressor diffuse large B cell lymphoma confined to a uterine leiomyoma: A case report.原发性、非生发中心、双表达弥漫性大B细胞淋巴瘤局限于子宫平滑肌瘤：一例报告

Gynecol Oncol Rep. 2017 Oct 18;22:78-81. doi: 10.1016/j.gore.2017.10.003. eCollection 2017 Nov.

Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.双打击淋巴瘤在利妥昔单抗时代构成弥漫性大 B 细胞淋巴瘤中极具侵袭性的亚组。

Jpn J Clin Oncol. 2012 Nov;42(11):1035-42. doi: 10.1093/jjco/hys148. Epub 2012 Sep 14.

Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation.双表达型淋巴瘤患者在接受异基因造血细胞移植后预后不良。

Biol Blood Marrow Transplant. 2018 Feb;24(2):294-300. doi: 10.1016/j.bbmt.2017.10.013. Epub 2017 Oct 14.

[MYC-associated B-cell lymphomas: pathophysiology and treatment].[MYC相关的B细胞淋巴瘤：病理生理学与治疗]

Rinsho Ketsueki. 2019;60(3):155-164. doi: 10.11406/rinketsu.60.155.

Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology.进一步探讨伴有 MYC 异常的大 B 细胞淋巴瘤的复杂性和母细胞样形态的重要性。

Am J Surg Pathol. 2017 Sep;41(9):1155-1166. doi: 10.1097/PAS.0000000000000818.

Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.极光抑制导致非整倍体和衰老的破坏促进双打击或双表达弥漫性大 B 细胞淋巴瘤的内在凋亡。

Mol Cancer Ther. 2017 Oct;16(10):2083-2093. doi: 10.1158/1535-7163.MCT-17-0089. Epub 2017 Jun 14.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.双打击和双表达型淋巴瘤患者接受异基因造血干细胞移植后的结果。

Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520. doi: 10.1016/j.bbmt.2017.11.023. Epub 2017 Nov 28.

引用本文的文献

Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.程序性死亡配体 1 在弥漫性大 B 细胞淋巴瘤中的表达：与临床病理预后因素的相关性。

J Egypt Natl Canc Inst. 2023 May 8;35(1):12. doi: 10.1186/s43046-023-00171-6.

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.在 PHOENIX 三期临床试验中，伊布替尼联合 R-CHOP 方案治疗未经治疗的同时表达 BCL2 和 MYC 的弥漫性大 B 细胞淋巴瘤的临床影响。

Blood Adv. 2023 May 23;7(10):2008-2017. doi: 10.1182/bloodadvances.2022009389.

Expression of c-Myc, Bcl2, Bcl6, and Cyclin D1 in High-Grade B-Cell Lymphoma.c-Myc、Bcl2、Bcl6和细胞周期蛋白D1在高级别B细胞淋巴瘤中的表达

Cureus. 2022 Sep 24;14(9):e29527. doi: 10.7759/cureus.29527. eCollection 2022 Sep.

The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.弥漫性大B细胞淋巴瘤患者中MYC和BCL2双重表达的发生率及治疗反应：一项系统评价和荟萃分析

Cancers (Basel). 2021 Jul 5;13(13):3369. doi: 10.3390/cancers13133369.

A case report of primary adrenal lymphoma: A rare but aggressive and invasive disease.原发性肾上腺淋巴瘤病例报告：一种罕见但具有侵袭性的疾病。

Medicine (Baltimore). 2020 Jul 10;99(28):e20938. doi: 10.1097/MD.0000000000020938.

本文引用的文献

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》

Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.

Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.免疫组织化学在MYC阳性侵袭性B细胞淋巴瘤基因检测时代的作用：一项209例病例的研究

J Clin Pathol. 2016 Mar;69(3):266-70. doi: 10.1136/jclinpath-2015-203002. Epub 2015 Aug 25.

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.通过数字基因表达确定福尔马林固定石蜡包埋组织活检中弥漫性大B细胞淋巴瘤细胞起源的预后意义

J Clin Oncol. 2015 Sep 10;33(26):2848-56. doi: 10.1200/JCO.2014.60.2383. Epub 2015 Aug 3.

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.MYC/BCL2 蛋白共表达有助于激活 B 细胞型弥漫性大 B 细胞淋巴瘤的生存预后不良，并表现出高危基因表达特征：来自国际弥漫性大 B 细胞淋巴瘤利妥昔单抗-CHOP 联合方案的报告。

Blood. 2013 May 16;121(20):4021-31; quiz 4250. doi: 10.1182/blood-2012-10-460063. Epub 2013 Feb 28.

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.免疫组化双打击评分是利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤患者预后的强有力预测指标。

J Clin Oncol. 2012 Oct 1;30(28):3460-7. doi: 10.1200/JCO.2011.41.4342. Epub 2012 Jun 4.

High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.核 MYC 蛋白高水平预示弥漫性大 B 细胞淋巴瘤存在 MYC 重排。

Am J Surg Pathol. 2012 Apr;36(4):612-9. doi: 10.1097/PAS.0b013e318244e2ba.

Non-Hodgkin lymphoma in Chile: a review of 207 consecutive adult cases by a panel of five expert hematopathologists.智利的非霍奇金淋巴瘤：由五位血液病理学家专家组对 207 例连续成年病例的回顾。

Leuk Lymphoma. 2012 Jul;53(7):1311-7. doi: 10.3109/10428194.2012.654471. Epub 2012 Mar 13.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.对于接受R-CHOP治疗的弥漫性大B细胞淋巴瘤患者，修订后的国际预后指数（R-IPI）比标准IPI能更好地预测预后。

Blood. 2007 Mar 1;109(5):1857-61. doi: 10.1182/blood-2006-08-038257. Epub 2006 Nov 14.

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.国际淋巴瘤研究组非霍奇金淋巴瘤分类的临床评估。非霍奇金淋巴瘤分类项目。

Blood. 1997 Jun 1;89(11):3909-18.

A predictive model for aggressive non-Hodgkin's lymphoma.侵袭性非霍奇金淋巴瘤的预测模型。

N Engl J Med. 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验